Skip to main content

Table 2 Patient data at baseline and after 6 months study period

From: Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure

  Baseline After 6 months
N 56 46
Dropped out N/A 10
BMI (kg/m2) 25.07 24.82
Blood pressure (SBP/DBP)(mmHg) 138 (9.67)/78.6 (11.5) 129.5 (10.62)/73.1 (12.0)*
Duration (y) 15.47 (10.67) 16.54 (10.88)
Laboratory data
HbA1c (%) 6.87 (0.68) 6.86 (0.93)
FPG (mg/dl) 151.7 (47.5) 137.02 (55.22)
HWM-AND (μg/ml) 4.89 (3.16) 5.87 (3.90)*
PAI-1 (mg/dl) 27.63 (16.28) 23.17 (7.43)*
VCAM-1 (mg/dl) 715.09 (173.70) 712.06 (196.04)
U-8-OHdG (pg/ml) 11.28 (3.22) 11.65 (3.15)
Hs-CRP (mg/dl) 0.093171 (0.015391) 0.099737 (0.015174)
Blood glucose lowering treatment
Insulin only 11 10
Insulin+OHA 7 7
OHA 32 24
Diet only 6 5
  1. BMI, body mass index; HbA1c, glycated hemoglobin A1c; FPG, fasting plasma glucose; HMW-ADN, high molecular weight-adiponectin; PAI-1, plasminogen activator inhibitor-1; VCAM-1, vascular cell adhesion molecule-1; U-8-OHdG, urinary-8-hydroxydeoxyguanosine; Hs-CRP, high-sensitivity C-reactive protein; OHA, oral hypoglycemic agent. Data are expressed as means±s.d. or n and%. *P<0.05.